{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:00:01Z","timestamp":1789016401986,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extramedullary (EM) lesions are common in multiple myeloma (MM) and are often related to the poor prognosis of MM but are scarcely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, the baseline characteristics of 357 newly diagnosed patients with extramedullary multiple myeloma (EMM) and their impact on the prognosis were analyzed. All patients received first-line treatment with bortezomib-based regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall incidence rate of EM was 22.4%, and the detection rate of PET\/CT was significantly higher than other imaging methods (P = 0.015). The cohorts consisted of 10 cases of extramedullary extraosseous (EME) and 70 cases of extramedullary-bone related (EMB), including 53 cases with single site involvement (one case with EME) and 27 cases with multiple sites (&amp;gt;1 site) involvement (nine cases with EME). EMM patients had high levels of hemoglobin (Hgb, \u226510 g\/dl) and serum lactate dehydrogenase (LDH, &amp;gt;245u\/L) and are inclined to early-stage revised international staging system (R-ISS). Compared to patients without EM, those with EMM had worse progression-free survival (PFS) (P = 0.014) and overall survival (OS) (P = 0.032). In addition, patients without EM and those with a single site of EMB had similar PFS and OS, while patients with multiple sites of EMB or EME and multiple sites of EMB with EME had poor PFS and OS. Multivariate analysis confirmed that multiple sites of EMB and\/or EME were independent prognostic predictors affecting PFS and OS in newly diagnosed MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggested that among patients treated with bortezomib-based regimens, multiple sites of EMB and\/or EME are independent poor prognostic factors for newly diagnosed MM patients, while a single site of EMB does not affect the survival of newly diagnosed MM patients. Thus, these findings could be used as a reference for the study of EMM patients in the new drug era, but prospective clinical studies are needed to provide evidence-based data for the diagnosis and treatment of EMM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2021.668099","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T12:29:38Z","timestamp":1625660978000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Multiple Extramedullary-Bone Related and\/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma"],"prefix":"10.3389","volume":"11","author":[{"given":"JingSong","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoYan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DongHua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GaoFeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enfan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoYan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenJun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary Multiple Myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17338","article-title":"Expert Review on Soft-Tissue Plasmacytomas in Multiple Myeloma: Definition, Disease Assessment and Treatment Considerations","author":"Rosinol","year":"2021","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of Paraosseous Extra-Medullary Disease in Newly Diagnosed Multiple Myeloma Patients Treated With New Drugs","volume":"105","author":"Montefusco","year":"2020","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178434","article-title":"Impact of Extramedullary Disease in Patients With Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219295","article-title":"A Real World Multicenter Retrospective Study on Extramedullary Disease From Balkan Myeloma Study Group and Barcelona University: Analysis of Parameters That Improve Outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I Treat Extramedullary Myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.561601","article-title":"Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Dat","volume":"11","author":"He","year":"2020","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284","article-title":"International Uniform Response Criteria for Multiple Myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2586","article-title":"Multiple Myeloma: Every Year a New Standard","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary Disease Portends Poor Prognosis in Multiple Myeloma and Is Over-Represented in High-Risk Disease Even in the Era of Novel Agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of Extramedullary Disease in Patients With Multiple Myeloma in the Era of Novel Therapy, and the Activity of Pomalidomide on Extramedullary Myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [(18)F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Stud","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the Diagnosis and Management of Multiple Myeloma and Other Plasma Cell Disorders: A Consensus Statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjz021","article-title":"Splenic Rupture Secondary to Amyloid Light-Chain (AL) Amyloidosis Associated With Multiple Myeloma","volume":"2019","author":"Buzalewski","year":"2019","journal-title":"J Surg Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6469196","article-title":"A 30-Year-Old Carrier of Gaucher Disease With Multiple Myeloma","volume":"2019","author":"Chadha","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Consecutive Patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802657751","article-title":"The Impact of Extramedullary Disease at Presentation on the Outcome of Myeloma","volume":"50","author":"Wu","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation T(14;16) and Multiple Myeloma: Is it Really an Independent Prognostic Factor","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.06.027","article-title":"Genetic Aberrations Including Chromosome 1 Abnormalities and Clinical Features of Plasma Cell Leukemia","volume":"33","author":"Chang","year":"2009","journal-title":"Leuk Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.12.013","article-title":"Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases","volume":"15","author":"Deng","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1038\/bcj.2017.90","article-title":"Current Applications of Multiparameter Flow Cytometry in Plasma Cell Disorders","volume":"7","author":"Jelinek","year":"2017","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5653.5653","article-title":"Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse","volume":"128","author":"Rihova","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","article-title":"Cytogenetics of Extramedullary Manifestations in Multiple Myeloma","volume":"161","author":"Billecke","year":"2013","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.160","article-title":"The Molecular Characterization and Clinical Management of Multiple Myeloma in the Post-Genome Era","volume":"23","author":"Zhou","year":"2009","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.07.004","article-title":"Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma With Extramedullary Disease and High-Risk Cytogenetics: A Study From the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantatio","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.668099\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T12:29:51Z","timestamp":1625660991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.668099\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":27,"alternative-id":["10.3389\/fonc.2021.668099"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.668099","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"article-number":"668099"}}